Biologics

The California Institute for Regenerative Medicine has been instrumental in stem cell research since it was first established in 2004, but it faces closure in 2022 if a ballot initiative to get it more funding is unsuccessful. 

Discgenics treated the first patients in its clinical trial of intervertebral disc tissue for mild to moderate degenerative disc disease in Japan, reports Biospectrum Asia.

Andreas Gomoll, MD, implanted Cartiheal's Agili-C in two patients in an investigational device exemption study at Hospital for Special Surgery in New York City.

NanoFuse Biologics is launching its biologic in Panama City, Panama, through a partnership with medical distributor PTY Medical Group.

Camber Spine is widening its portfolio by tapping into the biologics market.

Biologics development company AgeX Therapeutics added Michael May, PhD, to its board of directors, returning it to full strength.

Chad Kurtenbach, MD, of Sioux Falls, S.D.-based Sanford Health is conducting a study of a stem cell treatment for patients with osteoarthritis in the knee.

Biologics has the potential to be the next transformative tool in the orthopedic surgeon's playbook, but the field still has a ways to go before it becomes a mainstream medicinal offering.

Health plan provider Gilsbar entered into a partnership with interventional orthopedic clinic network Regenexx to provide beneficiaries access to reduced-cost musculoskeletal care options.

The California Institute for Regenerative Medicine was never supposed to last infinitely, but a new ballot initiative could extend its lifespan, Nature reports.